Rupatadin

Small molecule

MMarcus Maurer

Rupatadin is one of 6 small molecule programs targeting Mastocytosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastocytosisActive, not recruiting

MastocytosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Mastocytosis

#DrugCompanyPhaseTrials

Rydapt

Novartis

Approved

—2

Plaquenil

Alnylam Pharmaceuticals

Approved

—3

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 4

Masitinib

AAB Science

Phase 2

2 5

Cromoglicate

LEO Pharma

Phase 2

1 6

Rupatadin

MMarcus Maurer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mastocytosis1 trial

Study on Mastocytosis for Rupatadine Treatment

Completed·MMarcus Maurer·Phase 2/3·NCT01481909·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rupatadin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rupatadin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rupatadin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marcus Maurer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMarcus Maurer

Rupatadin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mastocytosis1 trial

References

Drug Info

Quick Facts

Related News